Expression of Glucocorticoid Induced TNF Receptor Family Related Protein (GITR) on peripheral T cells from normal human donors and patients with non-infectious uveitis

Journal of Autoimmunity

Volumn 21, Issue 1, 2003, Pages 83-92

  Li, Zhuqing ^a   Mahesh, Sankaranarayana P ^a   Kim, Ben J ^a   Buggage, Ronald R ^a   Nussenblatt, Robert B ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

FACS; GITR; Non infectious uveitis; Regulatory T cells; T helper cells

Indexed keywords

CD4 ANTIGEN; GLUCOCORTICOID; INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; AUTOIMMUNITY; CELL ACTIVATION; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; HELPER CELL; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; UVEITIS;

EID: 0038105200     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-8411(03)00085-4     Document Type: Article

References (31)

1. Nocentini G., Giunchi L., Ronchetti S., Krausz L.T., Bartoli A., Moraca R., et al. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc Natl Acad Sci U S A. 94:1997;6216-6221.
2. Gurney A.L., Marsters S.A., Huang R.M., Pitti R.M., Mark D.T., Baldwin D.T., et al. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol. 9:1999;215-218.
3. Kwon B., Yu K.Y., Ni J., Yu G.L., Jang I.K., Kim Y.J., et al. Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand. J Biol Chem. 274:1999;6056-6061.
4. Ronchetti S., Nocentini G., Riccardi C., Pandolfi P.P. Role of GITR in activation response of T lymphocytes. Blood. 100:2002;350-352.
5. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 101:2000;455-458.
6. Sakaguchi S., Takahashi T., Yamazaki S., Kuniyasu Y., Itoh M., Sakaguchi N., et al. Immunologic self tolerance maintained by T-cell-mediated control of self-reactive T cells: implications for autoimmunity and tumor immunity. Microbes Infect. 3:2001;911-918.
7. Shevach E.M. Regulatory T cells in autoimmmunity* Annu Rev Immunol. 18:2000;423-449.
8. Shevach E.M., McHugh R.S., Thornton A.M., Piccirillo C., Natarajan K., Margulies D.H. Control of autoimmunity by regulatory T cells. Adv Exp Med Biol. 490:2001;21-32.
9. Shimizu J., Yamazaki S., Takahashi T., Ishida Y., Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 3:2002;135-142.
10. McHugh R.S., Whitters M.J., Piccirillo C.A., Young D.A., Shevach E.M., Collins M., et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity. 16:2002;311-323.
11. Levings M.K., Sangregorio R., Sartirana C., Moschin A.L., Battaglia M., Orban P.C., et al. Human CD25(+)CD4(+) T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from Type 1 T regulatory cells. J Exp Med. 196:2002;1335-1346.
12. Nussenblatt R.B. The natural history of uveitis. Int Ophthalmol. 14:1990;303-308.
13. Caspi R.R., Roberge F.G., Chan C.C., Wiggert B., Chader G.J., Rozenszajn L.A., et al. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol. 140:1988;1490-1495.
14. Gery I., Chanaud N.P. 3rd, Anglade E. Recoverin is highly uveitogenic in Lewis rats. Invest Ophthalmol Vis Sci. 35:1994;3342-3345.
15. Nussenblatt R.B., Gery I. Experimental autoimmune uveitis and its relationship to clinical ocular inflammatory disease. J Autoimmun. 9:1996;575-585.
16. Nussenblatt R.B. Proctor Lecture. Experimental autoimmune uveitis: mechanisms of disease and clinical therapeutic indications. Invest Ophthalmol Vis Sci. 32:1991;3131-3141.
17. Nussenblatt R.B., Fortin E., Schiffman R., Rizzo L., Smith J., Van Veldhuisen P., et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A. 96:1999;7462-7466.
18. Whitcup S.M., Nussenblatt R.B. Immunologic mechanisms of uveitis. New targets for immunomodulation. Arch Ophthalmol. 115:1997;520-525.
19. Caspi R.R. Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int Rev Immunol. 21:2002;197-208.
20. Caspi R.R., Sun B., Agarwal R.K., Silver P.B., Rizzo L.V., Chan C.C., Wiggert B., Wilder R.L. T cell mechanisms in experimental autoimmune uveoretinitis: susceptibility is a function of the cytokine response profile. Eye. 11:(Pt 2):1997;209-212.
21. Xu H., Rizzo L.V., Silver P.B., Caspi R.R. Uveitogenicity is associated with a Th1-like lymphokine profile: cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis. Cell Immunol. 178:1997;69-78.
22. McDyer J.F., Li Z., John S., Yu X., Wu C.Y., Ragheb J.A. IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-gamma production. J Immunol. 169:2002;2736-2746.
23. Nussenblatt R.B., Gery I., Wacker W.B. Experimental autoimmune uveitis: cellular immune responsiveness. Invest Ophthalmol Vis Sci. 19:1980;686-690.
24. Foxman E.F., Zhang M., Hurst S.D., Muchamuel T., Shen D., Wawrousek E.F., et al. Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Th1- versus Th2-mediated ocular inflammation. J Immunol. 168:2002;2483-2492.
25. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 155:1995;1151-1164.
26. Stephens L.A., Mottet C., Mason D., Powrie F. Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol. 31:2001;1247-1254.
27. Taylor P.A., Noelle R.J., Blazar B.R. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med. 193:2001;1311-1318.
28. Horwitz D.A., Gray J.D., Zheng S. The potential of human regulatory T cells generated ex vivo as a treatment for lupus and other chronic inflammatory diseases. Arthritis Res. 4:2002;241-246.
29. Woo E.Y., Yeh H., Chu C.S., Schlienger K., Carroll R.G., Riley J.L., et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 168:2002;4272-4276.
30. Woo E.Y., Chu C.S., Goletz T.J., Schlienger K., Yeh H., Coukos G., et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61:2001;4766-4772.
31. Kukreja A., Cost G., Marker J., Zhang C., Sun Z., Lin-Su K., et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest. 109:2002;131-140.